GuoLine Advisory’s Novo Nordisk NVO Stock Holding History

GuoLine Advisory’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$20.5M	Hold	426,700	–	–	1.91%	20
2026 Q1	$15.7M	Hold	426,700	–	–	1.64%	21
2025 Q4	$21.7M	Hold	426,700	–	–	2%	21
2025 Q3	$23.7M	Hold	426,700	–	–	2.36%	20
2025 Q2	$29.5M	Hold	426,700	–	–	3.12%	16
2025 Q1	$29.6M	Buy	426,700 +80,200	+23%	+$6.62M	3.14%	16
2024 Q4	$29.8M	Buy	346,500 +58,900	+20%	+$6.37M	3.08%	17
2024 Q3	$34.2M	Hold	287,600	–	–	3.49%	14
2024 Q2	$41.1M	Hold	287,600	–	–	4.38%	9
2024 Q1	$36.9M	Buy	287,600 +110,000	+62%	+$13.1M	4.5%	11
2023 Q4	$18.4M	Buy	+177,600	New	+$17.6M	2.91%	13

Other funds holding NVO

SRIM

Saratoga Research & Investment Management Saratoga, California $1.83B AUM 18.41% 1-Year Est. Return

Markel Group Glen Allen, Virginia $13.1B AUM 15.62% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

AIIMS

Analyst IMS Investment Management Services Tel-Aviv, Israel $4.3B AUM 37.33% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

QV Investors Calgary, Alberta, Canada $1.3B AUM 31.14% 1-Year Est. Return

ABC Arbitrage Paris, France $926M AUM 45.9% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

GIM

Generate Investment Management Auckland, New Zealand $2.43B AUM 37.24% 1-Year Est. Return

GuoLine Advisory's NVO Position: Q2 2026 in Review

GuoLine Advisory held its Novo Nordisk (NVO) position steady in Q2 2026 at 426,700 shares worth $20.5M. The position accounts for 1.91% of the portfolio, ranked #20.

GuoLine Advisory first reported a position in NVO in Q4 2023 and has held it in 11 quarters since. The position peaked at $41.1M in Q2 2024. 580 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

GuoLine Advisory held 426,700 shares of Novo Nordisk worth $20.5M as of Q2 2026.
GuoLine Advisory left its Novo Nordisk share count unchanged in Q2 2026.
Novo Nordisk made up 1.91% of GuoLine Advisory's portfolio in Q2 2026, its #20 holding.
GuoLine Advisory first reported a position in Novo Nordisk in Q4 2023 and has held it in 11 quarters since.
GuoLine Advisory's Novo Nordisk position peaked at $41.1M in Q2 2024.
580 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on GuoLine Advisory's 13F filing for Q2 2026, filed 16 Jul 2026.